Hedeker Wealth’s Harmony Biosciences HRMY Stock Holding History

Hedeker Wealth’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.68M	Sell	46,257 -14,608	-24%	-$461K	0.32%	63
2026 Q1	$1.7M	Sell	60,865 -12,705	-17%	-$417K	0.36%	61
2025 Q4	$2.75M	Sell	73,570 -6,675	-8%	-$219K	0.58%	48
2025 Q3	$2.21M	Buy	80,245 +1,340	+2%	+$46.2K	0.46%	52
2025 Q2	$2.49M	Buy	78,905 +1,171	+2%	+$37.7K	0.58%	48
2025 Q1	$2.58M	Buy	77,734 +1,531	+2%	+$54.9K	0.69%	47
2024 Q4	$2.62M	Buy	76,203 +916	+1%	+$31.5K	0.65%	46
2024 Q3	$3.01M	Buy	75,287 +2,662	+4%	+$93.5K	0.8%	45
2024 Q2	$2.19M	Sell	72,625 -5,598	-7%	-$168K	0.64%	49
2024 Q1	$2.63M	Buy	+78,223	New	+$2.51M	0.76%	48

Other funds holding HRMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hedeker Wealth's HRMY Position: Q2 2026 in Review

Hedeker Wealth reduced its Harmony Biosciences (HRMY) stake by 24% in Q2 2026, selling an estimated $461K and leaving 46,257 shares worth $1.68M. The position accounts for 0.32% of the portfolio, ranked #63.

Hedeker Wealth first reported a position in HRMY in Q1 2024 and has held it in 10 quarters since. The position peaked at $3.01M in Q3 2024. 328 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

Hedeker Wealth held 46,257 shares of Harmony Biosciences worth $1.68M as of Q2 2026.
Hedeker Wealth sold 14,608 Harmony Biosciences shares in Q2 2026, an estimated $461K.
Harmony Biosciences made up 0.32% of Hedeker Wealth's portfolio in Q2 2026, its #63 holding.
Hedeker Wealth first reported a position in Harmony Biosciences in Q1 2024 and has held it in 10 quarters since.
Hedeker Wealth's Harmony Biosciences position peaked at $3.01M in Q3 2024.
328 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Hedeker Wealth's 13F filing for Q2 2026, filed 4 Aug 2026.